Author details

Full Name

Victor E Velculescu

Affiliation

ORCID

Career Start Year

1993

Papers

197

H Index

110

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37939140	Elucidating the Heterogeneity of Immunotherapy Response and Immune-Related Toxicities by Longitudinal ctDNA and Immune Cell Compartment Tracking in Lung Cancer.	Clin Cancer Res	2024
37500728	Single-molecule genome-wide mutation profiles of cell-free DNA for non-invasive detection of cancer.	Nat Genet	2023
36399356	Detecting Liver Cancer Using Cell-Free DNA Fragmentomes.	Cancer Discov	2023
37841875	Dual blockade of BRD4 and ATR/WEE1 pathways exploits <i>ARID1A</i> loss in clear cell ovarian cancer.	Res Sq	2023
37696619	Cell-free DNA approaches for cancer early detection and interception.	J Immunother Cancer	2023
37345659	H2Bub1 loss is an early contributor to clear cell ovarian cancer progression.	JCI Insight	2023
37087533	Potential utility of risk stratification for multicancer screening with liquid biopsy tests.	NPJ Precis Oncol	2023
37024582	Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer.	Nat Genet	2023
36702947	Persistent mutation burden drives sustained anti-tumor immune responses.	Nat Med	2023
37456850	Derivation of CD8<sup>+</sup> TÂ cell infiltration potentiators in non-small-cell lung cancer through tumor microenvironment analysis.	iScience	2023
37071497	Dynamics of Sequence and Structural Cell-Free DNA Landscapes in Small-Cell Lung Cancer.		2023
37121856	Corrigendum to "HLA class II immunogenic mutation burden predicts response to immune checkpoint blockade": [Annals of Oncology volume 33 (2022) 728-738].	Ann Oncol	2023
37116747	Cell-Free DNA Fragmentomes in the Diagnostic Evaluation of Patients With Symptoms Suggestive of Lung Cancer.		2023
37425893	Elucidating the heterogeneity of immunotherapy response and immune-related toxicities by longitudinal ctDNA and immune cell compartment tracking in lung cancer.		2023
36534496	Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells.	Clin Cancer Res	2023
35339648	HLA class II immunogenic mutation burden predicts response to immune checkpoint blockade.	Ann Oncol	2022
35773881	Natural Language Processing Approaches for Retrieval of Clinically Relevant Genomic Information in Cancer.		2022
36350985	Translating the evolving molecular landscape of tumors to biomarkers of response for cancer immunotherapy.	Science Translational Medicine	2022
35688557	Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy.	Journal for ImmunoTherapy of Cancer	2022
35803904	Reply to: Limitations of molecular testing in combination with computerized tomographic for lung cancer screening.	Nature Communications	2022
35595835	Automated next-generation profiling of genomic alterations in human cancers.	Nat Commun	2022
34750557	Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial.	Nat Med	2021
34290408	Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers.	Nature	2021
33306984	Conserved Interferon-Î³ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma.	Cancer Cell	2021
34608287	Author Correction: Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers.	Nature	2021
34820593	<i>KRAS</i> A146 Mutations Are Associated With Distinct Clinical Behavior in Patients With Colorectal Liver Metastases.	JCO Precis Oncol	2021
34417454	Detection and characterization of lung cancer using cell-free DNA fragmentomes.	Nat Commun	2021
33294860	Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma.	Cell Rep Med	2020
31988276	White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer.	Nat Commun	2020
31754049	Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non-Small Cell Lung Cancer.	Clinical Cancer Research	2020
32709856	Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models.	Nat Commun	2020
32984843	Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer.	Nat Cancer	2020
32929052	Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer.	Journal for ImmunoTherapy of Cancer	2020
32866655	Inherited Rare, Deleterious Variants in ATM Increase Lung Adenocarcinoma Risk.	J Thorac Oncol	2020
31373686	Genome-wide investigation of intragenic DNA methylation identifies ZMIZ1 gene as a prognostic marker in glioblastoma and multiple cancer types.	Int J Cancer	2019
30541742	Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.	Cancer Res	2019
30573519	Early Noninvasive Detection of Response to Targeted Therapy in Non-Small Cell Lung Cancer.	Cancer Res	2019
31142840	Genome-wide cell-free DNA fragmentation in patients with cancer.	Nature	2019
31142500	Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer.	Clin Cancer Res	2019
31506389	Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade.	Clin Cancer Res	2019
30744692	Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1.	J Immunother Cancer	2019
31471313	Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors.	Clinical Cancer Research	2019
30679390	Combined MEK and BCL-2/X<sub>L</sub> Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient-Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness.	Mol Cancer Ther	2019
30841906	Correction to: persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1.	J Immunother Cancer	2019
29658848	Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.	New England Journal of Medicine	2018
31799491	<i>BRAF</i> Mutations Occur Infrequently in Ovarian Cancer but Suggest Responsiveness to BRAF and MEK Inhibition.	JCO Precis Oncol	2018
29983880	Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer.	Oncotarget	2018
29982279	Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC).	Ann Oncol	2018
30485824	Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines.	Cell Rep	2018
30185652	A machine learning approach for somatic mutation discovery.	Sci Transl Med	2018